Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
abuse, ACA, adding, Antibody, apportioned, ASU, brand, branded, calendar, cGMP, checkpoint, creation, domestic, EADO, Engineered, enhanced, ESMO, family, FASB, fraud, goal, highlighting, immune, ipilimumab, Kingdom, Madrid, nivolimab, nondeductible, outpatient, oversee, pembrolizumab, Poverty, ramp, ratably, Spain, Statute, teaching
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.2 Form of Stock Option Agreement Under the 2014 Equity Incentive Plan
- 10.3 Form of Stock Option Agreement (International) Under the 2014 Eip
- 10.4 Form of Stock Option Agreement (Non-employee Director) Under the 2014 Eip
- 10.5 Form of Restricted Stock Unit Agreement Under the 2014 Equity Incentive Plan
- 10.6 Form of Stock Option Agreement (International) Under the 2011 Eip
- 10.7 Transition & Consulting Agreement DTD May 7, 2014 Between Exelixis & Frank Karbe
- 10.8 Offer Letter Agreement, Dated May 9, 2005, Between Exelixis and Deborah Burke
- 10.9 Special One-time Bonus Memorandum for Deborah Burke Dated May 15, 2014
- 10.10 Collaboration Agreement, Dated May 27, 2009, Between Exelixis, Inc. and Sanofi
- 12.1 Statement Re Computation of Earnings to Fixed Charges
- 31.1 Certification of CEO Required by Rule 13A-14(A) or Rule 15D-14(A)
- 31.2 Certification of CFO Required by Rule 13A-14(A) or Rule 15D-14(A)
- 32.1 Certification of CEO and CFO Required by Rule 13A-14(B) or Rule 15D-14(B)
- Download Excel data file
- View Excel data file
Related press release
EXEL similar filings
Filing view
External links